Rio Tinto's California Boron Assets Attract Over a Dozen Bidders, Valued at Up to $2 Billion 
Tokyo Electric Power Attracts Major Investors Amid Billion-Dollar Restructuring Push 
Chalco Stock Surges as Q1 2025 Profit Forecast Jumps Up to 58% 
U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market 
Goldman Sachs, ANZ Cut Oil Forecasts Amid U.S.-Iran Ceasefire Hopes 
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts 
San Francisco Suspect Arrested After Molotov Cocktail Attack on OpenAI CEO Sam Altman's Home 
China's AI Stocks Surge as Zhipu and MiniMax Hit Record Highs 
Chinese Brands Are Taking Over Brazil — And It's Just Getting Started 
Anthropic Fights Pentagon Blacklisting in Dual Federal Court Battles 
NIO ES9 SUV Launch Sends HK Shares Down 7% Despite Bold Pricing Strategy 
MATCH Act: How New U.S. Chip Legislation Could Freeze China's Semiconductor Ambitions 
BHP's Incoming CEO Visits China Amid Pricing Dispute with CMRG 
Chinese Cars in Europe: Consumer Trust Is Shifting Fast 
TSMC Posts Strong Q1 2025 Revenue, Riding AI Chip Demand Wave 
SanDisk Joins Nasdaq-100, Replacing Atlassian on April 20 
Pilots Fear Retaliation for Refusing Middle East Flights Amid Ongoing Conflict 
LUND, Sweden, April 28, 2016 --
Laquinimod
- The clinical Phase 3 study CONCERTO, 0.6 mg/day, in relapsing remitting multiple sclerosis (RRMS), with the aim to obtain market approval in the US and Europe, is proceeding according to plan. Study results are expected in the first half of 2017
- The clinical Phase 2 study ARPEGGIO for the treatment of primary progressive multiple sclerosis (PPMS) is proceeding according to plan
- The clinical Phase 2 study LEGATO-HD for the treatment of Huntington's disease is proceeding according to plan
- Extension studies with 0.6 mg laquinimod in patients from the Phase 3 studies ALLEGRO and BRAVO are proceeding according to plan
- As earlier communicated the highest dose groups in the clinical studies CONCERTO, ARPEGGIO and LEGATO-HD have been discontinued due to cardiovascular events
Tasquinimod
- In March 2016, it was announced that the company plans to develop tasquinimod to treat multiple myeloma and intends to seek a collaboration partner for the project
- An expanded analysis of the secondary endpoints in the 10TASQ10 study was presented at the ASCO GU Symposium in January 2016. The results showed that tasquinimod had positive effects on both radiographic and PSA-based endpoints. However, as previously communicated, overall survival (OS) was not extended, prompting the discontinuation of all further development within prostate cancer
ANYARA, Paquinimod (57-57) and SILC (ISI)
- Out-licensing activities are continuing
Financial summary
| MSEK | Jan. - Mar. | Full Year | |||
| 2016 | 2015 | 2015 | |||
| Net sales | 3.9 | 2.9 | 16.3 | ||
| Operating loss | -16.1 | -57.4 | -177.9 | ||
| Loss for the period | -16.8 | -58.0 | -193.5 | ||
| Loss per share, before and after dilution (SEK) | -0.19 | -0.64 | -2.15 | ||
| Cash and cash equivalents (at the end of the period) | 76.5 | 270.5 | 103.6 | ||
For further information, please contact:
Tomas Leanderson, President and CEO
Tel: +46 (0)46 19 20 95
Hans Kolam, CFO
Tel: +46 (0)46 19 20 44
Active Biotech AB
(Corp. Reg. No. 556223-9227)
Box 724, SE-220 07 Lund, Sweden
Tel: +46 (0)46 19 20 00
Fax: +46 (0)46 19 11 05
The report is also available at www.activebiotech.com.
Active Biotech AB (publ) Interim report January - March 2016 http://hugin.info/1002/R/2007548/742184.pdf
HUG#2007548
